Free tool
FAERS Monitor: Qbrexza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210361 or its brand name (Qbrexza, Glycopyrronium Tosylate). Reports on generic versions are filed under their own applications.
Reports
1,551
Serious
788
51% of reports
Hospitalization
414
Death reported
99
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- mydriasis273
- dry mouth241
- off label use195
- vision blurred188
- drug ineffective97
- intentional product misuse94
- urinary retention89
- headache85
- constipation72
- dyspnoea69
- pneumonia59
- nausea54
- wrong technique in product usage process54
- hyperhidrosis51
- oropharyngeal pain51
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 8 |
| 2015 | 17 |
| 2016 | 37 |
| 2017 | 39 |
| 2018 | 57 |
| 2019 | 491 |
| 2020 | 226 |
| 2021 | 170 |
| 2022 | 89 |
| 2023 | 106 |
| 2024 | 121 |
| 2025 | 103 |
| 2026 | 65 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,608 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mydriasisSignal | 273 | 294.8 | 264.3 | 77,989 |
| dry mouthSignal | 241 | 40.4 | 36.0 | 9,229 |
| urinary retentionSignal | 89 | 36.3 | 29.6 | 3,014 |
| vision blurredSignal | 188 | 18.6 | 16.3 | 3,128 |
| intentional product misuseSignal | 94 | 14.6 | 12.0 | 1,179 |
| oropharyngeal painSignal | 51 | 7.5 | 5.7 | 281 |
| hyperhidrosisSignal | 51 | 5.4 | 4.1 | 178 |
| constipationSignal | 72 | 4.5 | 3.6 | 193 |
| wrong technique in product usage processSignal | 54 | 3.6 | 2.8 | 100 |
| off label useSignal | 195 | 3.0 | 2.6 | 273 |
| pneumoniaSignal | 59 | 2.5 | 1.9 | 51 |
| headache | 85 | 1.8 | 1.5 | 33 |
| dyspnoea | 69 | 1.7 | 1.3 | 18 |
| drug ineffective | 97 | 1.0 | 0.8 | 0 |
| nausea | 54 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.